SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 12, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	181	35	63	30	340	-
Market Cap Growth	548.61%	-44.79%	113.36%	-91.25%	-	-
Enterprise Value	74	9	66	27	336	-
Last Close Price	3.59	3.79	6.88	5.90	78.10	-
PS Ratio	1556.48	26.48	28.33	1.24	5.58	-
PB Ratio	1.03	1.35	1.11	0.96	8.81	-
P/TBV Ratio	1.08	1.35	1.11	0.96	8.81	-
P/OCF Ratio	-	-	-	-	170.89	-
EV/Sales Ratio	643.71	6.91	29.32	1.14	5.51	-
Debt / Equity Ratio	0.04	0.18	0.10	0.19	0.22	0.21
Debt / EBITDA Ratio	-	-	-	-	-	0.38
Asset Turnover	0.00	0.02	0.03	0.36	0.88	1.48
Quick Ratio	10.33	2.61	5.23	1.37	1.56	3.00
Current Ratio	10.50	2.98	5.45	1.47	1.90	3.12
Return on Equity (ROE)	18.56%	-81.92%	-95.51%	-53.85%	-44.21%	86.15%
Return on Assets (ROA)	-22.76%	-41.86%	-35.30%	-27.37%	-12.16%	34.47%
Return on Capital (ROIC)	-25.39%	-57.16%	-47.50%	-43.00%	-17.77%	41.14%
Return on Capital Employed (ROCE)	-25.00%	-118.50%	-52.10%	-80.50%	-24.50%	45.20%
Earnings Yield	-2.40%	-97.39%	-66.52%	-63.04%	-5.05%	-
FCF Yield	-21.05%	-98.89%	-39.91%	-86.20%	-2.64%	-
Buyback Yield / Dilution	-11.66%	-67.74%	-26.86%	-59.20%	-1.21%	23.30%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q